Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Microbix Biosystems Inc. , a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its first ...

Using the new LillyDirect service, Zepbound (tirzepatide ... It is one of the first examples of a big pharma taking a DTC approach in which a patient’s prescription goes straight to the company ...

Hims and Hers is airing an ad about its copycat GLP-1 drugs during Sunday’s Super Bowl. Critics say it violates FDA rules.

February 6, 2025 • U.S. foreign aid is in the crosshairs of the Trump administration. Workers at USAID woke up on Wednesday to an order putting nearly all personnel of the foreign assistance ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Zepbound is a subcutaneous injection that needs proper storage and handling during travel. There are ways you can travel with Zepbound to ensure it remains safe and effective to use. Zepbound ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...